Hyper-androgenemia and obesity in early-pubertal girls

T. Durá-Travé1,2,3 · F. Gallinas-Victoriano2,3

Received: 15 January 2022 / Accepted: 28 March 2022 / Published online: 12 April 2022 © The Author(s) 2022

Abstract

Purpose The aim of this study was to examine the hormonal profile in early-pubertal girls with obesity. We hypothesized that these patients might already present hormonal alterations with POCS-like features.

Methods Cross-sectional study in a sample of 283 peri-pubertal girls (prepubertal and early-puberty subgroups), aged 6.1–12.0 years, diagnosed with obesity (BMI-SDS > 2.0, 97th percentile), so-called obesity group. They all underwent clinical examination and blood testing for hormonal measurements (leptin, TSH, FT4, IGF-1, IGFBP3, prolactin, insulin, FSH, LH, estradiol, ACTH, cortisol, 17-OH-P, DHE-S, androstenedione, testosterone and free testosterone). A control group was recruited: 243 healthy girls, aged 6.3–12.1 years, with normal BMI status.

Results Prepubertal girls with obesity had significantly higher values \(p<0.05\) for BMI-SDS, leptin, insulin and HOMA-IR levels than control group. Early-pubertal girls with obesity also had significantly higher values \(p<0.05\) for BMI-SDS, leptin, IGF-1, IGFBP3, insulin and HOMA-IR, LH, ratio LH/FSH, ACTH, DHE-S, androstenedione, testosterone and free testosterone levels than control group. In early-pubertal girls with obesity (not prepubertal girls), there was a positive correlation \(p<0.01\) between leptin levels with LH, androstenedione and testosterone, and HOMA-IR with LH and testosterone levels. There was also a positive correlation \(p<0.01\) between IGF-1 levels with LH, androstenedione, DHE-S and testosterone; and LH levels with testosterone.

Conclusion The results obtained support our hypothesis that an abnormal hormonal profile with POCS-like features can already be detected (insulin resistance and hyperinsulinemia, increased secretion of LH and ACTH, and overproduction of ovarian and adrenal androgens) in early-pubertal girls with obesity.

Keywords Androgen · Girls · Hormone profile · Obesity comorbidities · Peri-pubertal

Introduction

Childhood obesity (children and adolescents) has progressed steadily in most countries in recent decades [1, 2]. In addition, childhood obesity is related to comorbidities potentially harmful to health condition, including hypertension, dyslipidemia, impaired glucose metabolism, obstructive sleep apnea, and non-alcoholic fatty liver disease [3–5]. In fact, it is currently considered as a public health problem of great importance given its social, economic and health repercussions [6].

On the other hand, several observational studies have revealed that excess adiposity could influence various aspects of pubertal development, such as the timing of pubertal onset (although this hypothesis remains controversial), or the hormonal parameters during puberty [7]. For example, peri-pubertal obesity in girls has been associated with hyper-androgenemia in some [8, 9], although not all, studies [10]; despite this, the mechanism underlying this relationship remains uncertain. In addition, it could be said that the sources of androgen overproduction (ovarian vs. adrenal) in overweight pubertal girls are still uncertain [11]. Furthermore, the association between peri-pubertal obesity and hyper-androgenemia could have a potential role in the genesis of polycystic ovarian syndrome (PCOS).
during adolescence or later in life [12, 13]. In fact, the PCOS is considered by various authors as a comorbidity of pediatric obesity [14, 15], and this would justify the interest in monitoring the hormonal profile during the different stages of puberty in these girls, especially in early puberty, to take possible preventive measures.

The aim of this study was to examine the hormonal profile in a group of peri-pubertal girls with obesity. We hypothesized that girls with obesity at early puberty might already present an abnormal hormonal profile with PCOS-like features.

Materials and methods

Participants

This is a cross-sectional study (convenience sample) conducted in a sample of 283 peri-puberal girls, aged 6.1–12.0 years, and diagnosed with obesity (BMI-SDS > 2.0, 97th percentile) or obesity group. They all underwent clinical examination and blood testing for hormonal measurements: leptin, thyrotropin (TSH), free thyroxine (FT4), insulin-like growth factor-1 (IGF-1), IGF-binding protein type 3 (IGFBP3), prolactin (PL), insulin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, adrenocorticotropic hormone (ACTH), cortisol, 17-hydroxyprogesterone (17-OH-P), dehydroepiandrosterone sulfate (DHE-S), androstenedione, total testosterone (T) and free testosterone (FT) in the Pediatric Endocrinology Unit of the Navarra Hospital Complex (Pamplona, Spain) in the period January 2013–December 2021.

In addition to that, these parameters (clinical examination and hormonal measurements) were determined in a control group that consisted of 243 healthy girls, aged 6.3–12.1 years, with normal nutritional status: BMI-SDS ranging from −1.0 (15th percentile) to +1.0 (85th percentile). These participants came from external consultations of the different pediatric subspecialties.

Breast development was assessed by both inspection and palpation and pubertal stage was determined in each participant according to Tanner’s criteria. In this way, the participants were classified in two different subgroups: pre-pubertal subgroup (Tanner breast stage I) and early-puberty subgroup (Tanner breast stages II). All participants were pre-menarchal girls.

All participants included in the study were Caucasian individuals with no previously detected chronic pathologies that might affect growth, body composition, food ingestion or physical activity. Girls who had a history of virilization (hirsutism, clitoromegaly, etc.), premature adrenarche or precocious puberty were excluded.

Adequate information of the proceedings and potential implications was delivered to the parents and/or legal guardians, and the corresponding consent was required prior to the inclusion in this study in all cases. The study was presented and subsequently approved after the evaluation of the Ethics Committee for Human Investigation at our institution (in line with the ethical standards stated in the Declaration of Helsinky 1964 and later amendments).

Clinical examination

Weight and height measurements were made in underwear while barefoot. Weight was measured using an Año-Sayol scale (reading interval 0 to 120 kg and a precision of 100 g), and height was measured using a Holtain wall stadiometer (reading interval 60 to 210 cm, precision 0.1 cm). The SDS values for the BMI were calculated using the epidemiologic data contained within the program Aplicación Nutricional, from the Spanish Society of pediatric gastroenterology, hepatology and nutrition (Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica, available at http://www.gastroinf.es/nutricional/). The graphics from Ferrándiz et al. (Centro Andrea Prader, Zaragoza 2002) used as reference charts [16].

Hormonal measurements

All hormonal determinations (leptin, TSH, FT4, IGF-1, IGFBP3), PL, insulin, FSH, LH, estradiol, ACTH, cortisol, 17-OH-P, DHE-S, androstenedione, T and FT were made after blood sample collection under basal fasting conditions (between 8:00 and 9:00 h after an overnight fast).

Hormonal measurements, when appropriate, were quantified by radio immuno-assay (Immuno Diagnostic System, Bolden, UK), enzyme-linked immunosorbent assay (Immunoassay, DPC Bierrmann, Bad Nauheim, Germany) or highly sensitive chemiluminescence immuno-assays (LIASON Assay, Diasorin, Dietzenbach, Germany). Homeostasis model-assessment (HOMA-IR) indexes were calculated from fasting glucose and insulin concentrations (glucose levels in mmol × insulin in μU/ml/L/22.5).

Statistical analysis

Results are displayed as means (M) with the corresponding confidence intervals (95% CI) or median and interquartile ranges. Mann–Whitney U test or Student’s t test was used to compare mean or median values in the variables recorded within groups and subgroups. Pearson’s test was used to quantify the degree of linear association between quantitative variables. Statistical analyses were performed using the program Statistical Packages for the Social Sciences version 20.0 (Chicago, IL, USA). Statistical significance was accepted when p value was <0.05.
Results

Table 1 shows and compares the mean values for the clinical characteristics (age and BMI-SDS) and hormonal determinations (leptin, TSH, FT4, IGF-1, PL, insulin and HOMA-IR) in prepubertal and early-puberty subgroups according to BMI status (control and obesity groups).

In prepubertal subgroup, girls with obesity had significantly higher values \( (p < 0.05) \) for BMI-SDS, leptin and insulin levels, and HOMA-IR index than control group, and there were no significant differences in age, TSH, FT4, IGF-1, IGFBP3, and PL levels among both groups. In early-puberty subgroup, girls with obesity had significantly higher values \( (p < 0.05) \) for BMI-SDS, leptin, IGF-1, IGFBP3 and insulin levels, and HOMA-IR index than control group, and there were no significant differences in age, TSH, FT4 and PL levels among both groups.

Table 2 shows and compares the mean values for the hormonal determinations (FSH, LH, estradiol, ACTH, cortisol, 17-OH-P, DHE-S, androstenedione, T and FT) in prepubertal and early-puberty subgroups in accordance to BMI status (control and obesity groups).

In the prepubertal subgroup, there were no significant differences in any hormonal measurements among both groups. In early-puberty subgroup, girls with obesity had significantly higher values \( (p < 0.05) \) for LH, ACTH, androstenedione, T and FT levels than control group, and there were no significant differences in age, FSH, estradiol, cortisol and 17-OH-P levels among both groups.

In control group, early-puberty subgroup girls had significantly higher values \( (p < 0.05) \) for age, IGF-1, IGFBP3, insulin, HOMA-IR, FSH, LH, ratio LH/FSH, estradiol, androstenedione, T and FT levels than prepubertal subgroup, and there were no significant differences in BMI-SDS, leptin, TSH, FT4, PL, ACTH, cortisol, 17-OH-P, and DHE-S levels among both subgroups.

In obesity group, early-puberty subgroup girls had significantly higher values \( (p < 0.05) \) for age, leptin, IGF-1, IGFBP3, insulin, HOMA-IR, FSH, LH, ratio LH/FSH, estradiol, ACTH, DHE-S, androstenedione, T and FT levels than prepubertal subgroup, and there were no significant differences in BMI-SDS, leptin, TSH, FT4, PL, insulin and HOMA-IR levels among both groups.

Table 1 Mean clinical characteristics (age and BMI-SDS) and hormonal measurements (leptin, TSH, FT4, IGF-1, IGFBP3, PL, insulin and HOMA-IR) in prepubertal and early subgroups according to the BMI status (M, 95% CI)

|                     | Control group \( (n=132) \) | Obesity group \( (n=165) \) | \( p \) values* |
|---------------------|-----------------------------|----------------------------|---------------|
| **Prepubertal subgroup** |                             |                             |               |
| Age (years)         | 8.1 (7.8–8.3)               | 8.1 (7.8–8.3)               | 0.864         |
| BMI-SDS             | −0.02 (−0.12/+0.08)         | 3.4 (3.2–3.6)               | 0.001         |
| Leptin (μg/L)       | 6.8 (4.1–9.6)               | 26.6 (24.3–29.0)            | 0.001         |
| TSH (mU/L)          | 2.0 (1.8–2.2)               | 2.1 (2.0–2.3)               | 0.301         |
| FT4 (ng/dL)         | 1.0 (0.9–1.0)               | 1.0 (0.9–1.1)               | 0.450         |
| IGF-1 (μg/L)        | 182.1 (168.9–195.4)         | 182.2 (170.7–193.6)         | 0.994         |
| IGFBP3 (μg/L)       | 4997.9 (4748.3–5247.4)      | 5238.1 (4910.1–5567.2)      | 0.235         |
| PL (μg/L)           | 11.8 (10.1–13.5)            | 11.3 (9.5–13.1)             | 0.681         |
| Insulin (mU/L)      | 7.2 (5.6–8.8)               | 14.4 (13.1–15.8)            | 0.001         |
| HOMA-IR             | 1.6 (1.2–1.9)               | 3.0 (2.7–3.3)               | 0.001         |

|                     | Control group \( (n=111) \) | Obesity group \( (n=118) \) | \( p \) values* |
|---------------------|-----------------------------|----------------------------|---------------|
| **Early puberty subgroup** |                             |                             |               |
| Age (years)         | 10.5 (10.0–11.0)            | 10.4 (9.9–10.8)             | 0.831         |
| BMI-SDS             | 0.10 (−0.01/+0.19)          | 3.3 (3.1–3.5)               | 0.001         |
| Leptin (μg/L)       | 8.8 (4.8–12.9)              | 45.2 (41.1–49.3)            | 0.001         |
| TSH (mU/L)          | 2.2 (2.1–2.3)               | 2.3 (2.1–2.6)               | 0.761         |
| FT4 (ng/dL)         | 1.02 (1.0–1.04)             | 1.01 (0.99–1.03)            | 0.823         |
| IGF-1 (μg/L)        | 260.6 (236.5–284.8)         | 367.4 (311.5–423.4)         | 0.001         |
| IGFBP3 (μg/L)       | 5636.4 (5315.9–5956.8)      | 6509.1 (5822.7–7195.4)      | 0.009         |
| PL (μg/L)           | 10.0 (8.5–11.4)             | 12.2 (9.6–14.8)             | 0.544         |
| Insulin (mU/L)      | 11.2 (9.1–13.3)             | 25.3 (22.4–28.1)            | 0.001         |
| HOMA-IR             | 2.4 (1.9–2.8)               | 4.9 (4.4–5.3)               | 0.001         |

*Student’s t test
significant differences in BMI-SDS, TSH, FT4, PL, cortisol and 17-OH-P levels among both subgroups.

In early-pubertal girls with obesity (not prepubertal girls), there was a positive correlation \( (p < 0.01) \) between BMI and HOMA-IR \( (r = 0.649) \), leptin \( (r = 0.627) \), and T \( (r = 0.424) \); as well as between leptin and LH \( (r = 0.464) \), androstenedione \( (r = 0.366) \) and T \( (r = 0.454) \) levels, and between HOMA-IR and LH \( (r = 0.489) \) and T \( (r = 0.416) \). In addition, there was a positive correlation \( (p < 0.01) \) between IGF-1 and LH \( (r = 0.689) \), androstenedione \( (r = 0.497) \), DHE-S \( (r = 0.486) \) and T \( (r = 0.404) \) levels, as well as between LH and T \( (r = 0.676) \) levels, and between T and FT \( (r = 0.768) \) levels.

### Discussion

This study features that hormonal profile in peri-pubertal girls with obesity is characterized by hyperinsulinemia and higher HOMA-IR index, especially evident in early puberty, compared to control group. Furthermore, in early puberty (not prepubertal girls), these girls with obesity showed higher levels of LH, ACTH, and androgens (DHEA-S, androstenedione, T and FT) than non-obese girls.

Insulin resistance and compensatory hyperinsulinemia are physiological during the peri-pubertal period, but insulin resistance may be overshadowed especially in peri-pubertal girls with obesity -as occurred in this study-, and is a frequent obesity-related comorbidity, as well as a risk factor for atherosclerotic cardiovascular disease and type 2 diabetes mellitus [4, 9, 15]. In this case, the analysis of this finding is quite interesting because experimental studies have revealed a relationship between hyper-androgenemia and hyperinsulinemia in peri-pubertal girls with obesity. As an example, insulin appears to stimulate androgen production in the ovarian theca cells even in the absence of LH, as well as to promote excessive androgen production by the adrenal glands. Hyperinsulinemia decreases

Table 2 Mean hormonal determinations (FSH, LH, ratio LH/FSH, estradiol, ACTH, cortisol, 17-OH-P, DHE-S, androstenedione, T and FT) in prepubertal and early subgroups according to the BMI status (M, 95% CI)

|                  | Control group \((n = 132)\) | Obesity group \((n = 165)\) | \( p \) values* |
|------------------|-----------------------------|-----------------------------|----------------|
| **Prepubertal subgroup** |                             |                             |                |
| FSH (UI/L)       | 1.5 (1.3–1.6)               | 1.6 (1.0–2.2)               | 0.754          |
| LH (UI/L)        | 0.05 (0.04–0.06)            | 0.050 (0.03–0.06)           | 0.275          |
| ratio LH/FSH     | 0.03 (0.03–0.04)            | 0.04 (0.03–0.04)            | 0.314          |
| Estradiol (pg/mL)| 9.1 (8.5–9.7)               | 9.5 (9.2–9.8)               | 0.126          |
| ACTH (ng/L)      | 19.8 (15.9–23.6)            | 22.3 (19.3–25.3)            | 0.299          |
| Cortisol (μg/dL) | 8.6 (7.7–0.6)               | 8.1 (7.2–0.9)               | 0.421          |
| 17-OH-P (μg/L)   | 0.8 (0.6–1.0)               | 0.80 (0.7–0.8)              | 0.435          |
| DHE-S (μg/dL)    | 61.0 (53.3–68.7)            | 71.7 (64.2–79.2)            | 0.253          |
| Androstenedione (μg/L) | 0.4 (0.3–0.5)   | 0.4 (0.3–0.4)               | 0.752          |
| Testosterone (ng/mL) | 0.1 (0.09–0.11) | 0.11 (0.10–0.12)           | 0.674          |
| FT (ng/L)        | 0.33 (0.27–0.39)            | 0.40 (0.32–0.48)            | 0.220          |

|                  | Control group \((n = 111)\) | Obesity group \((n = 118)\) | \( p \) values* |
|------------------|-----------------------------|-----------------------------|----------------|
| **Early puberty subgroup** |                             |                             |                |
| FSH (UI/L)       | 3.7 (3.3–4.1)               | 3.8 (3.5–4.2)               | 0.529          |
| LH (UI/L)        | 0.7 (0.5–0.9)               | 2.5 (2.0–2.9)               | 0.001          |
| ratio LH/FSH     | 0.19 (0.15–0.24)            | 0.6 (0.5–0.7)               | 0.001          |
| Estradiol (pg/mL)| 24.6 (17.6–31.5)            | 31.0 (24.4–37.5)            | 0.310          |
| ACTH (ng/L)      | 18.1 (14.9–21.1)            | 29.6 (24.8–34.3)            | 0.003          |
| Cortisol (μg/dL) | 9.2 (6.8–11.5)              | 11.5 (9.6–13.3)             | 0.389          |
| 17-OH-P (μg/L)   | 0.8 (0.7–1.0)               | 0.9 (0.7–1.1)               | 0.318          |
| DHE-S (μg/dL)    | 69.6 (61.0–78.3)            | 143.8 (130.6–156.9)         | 0.001          |
| Androstenedione (μg/L) | 0.6 (0.5–0.7)   | 1.4 (1.2–1.6)               | 0.001          |
| Testosterone (ng/mL) | 0.14 (0.10–0.18) | 0.23 (0.21–0.25)           | 0.001          |
| FT (ng/L)        | 0.6 (0.4–0.7)               | 1.3 (1.1–1.3)               | 0.001          |

*Student’s \( t \) test
hepatic production of sex hormone-binding globulin (SHBG) resulting in increased androgen bioavailability (i.e., increased free testosterone), and these abnormalities appear to reverse with weight loss [17]. Even more, it appears that insulin also directly up-regulates 17-hydroxysteroid dehydrogenase gene expression and activity, stimulating testosterone formation from androstenedione in the ovaries and zona reticularis of the adrenal cortex [18]. In the present study, as several authors have previously described [8, 9, 12], we found a significant correlation between insulin resistance (HOMA-IR index) and testosterone (total and free fraction) in early-pubertal girls with obesity. Although the pathophysiology of hyper-androgenemia in peri-pubertal girls with obesity is yet unclear, insulin resistance with compensatory hyperinsulinemia probably plays a key role [9]. Therefore, although prepubertal girls with obesity did not show hyper-androgenism in this study, they should be regularly monitored because they already had higher insulin and HOMA-IR levels than the control group [19]. The application of an extensive combined dietetic behavioral–physical activity intervention helps improve cardiovascular risk factors, such as hypertension, dyslipidemia, and insulin resistance [20]; and some authors have reported that androgen levels improve after sustained weight loss [14, 17]. However, additional studies are required to determine if weight loss and/or pharmacological treatment could improve insulin resistance and decrease androgen levels in these patients.

Under normal conditions, androgens and androgen precursors are normally secreted by both the ovaries and the adrenal glands in response to their respective trophic hormones, LH and ACTH. Approximately half of testosterone is produced by direct secretion of the ovaries and adrenal glands, while the other half is produced by peripheral conversion of circulating androstenedione mainly in liver, skin and fat [21]. In fact, obesity itself increases androgen production and peripheral conversion of androstenedione to testosterone in adipose tissue. The factors regulating these conversions are unclear, although insulin, IGF-1, and leptin have been suggested as determinants in stimulating testosterone synthesis in fat [22, 23]. In our study, we found a significant correlation between BMI-SDS and leptin with androstenedione and testosterone levels, suggesting, as some authors support, that excess adipose tissue appears to be an important factor to androgen excess in these patients [19, 21, 24, 25].

Total IGF-1 and IGFBP3 concentrations in subjects with obesity are mildly elevated, as we observed in this study, but free IGF-1 levels are increased. The latter may reflect reductions in circulating IGBP-1 and IGFB2, which are suppressed by insulin and correlate inversely with insulin sensitivity [26]. Together with nutrients excess, the increase in free IGF-1 levels may accelerate linear growth and bone age in peri-pubertal period and, with hyperinsulinemia, it would contribute to adrenal and ovarian androgen production [27]. In fact, we also found in early-pubertal girls with obesity a significant correlation between IGF-1 and androgen levels (DHE-S, androstenedione and testosterone). Additional studies are needed to corroborate the presumed relationship between IGF-1 and overproduction of androgens.

In compliance with several studies [8, 9], we also found that the hormonal profile in early-pubertal girls with obesity showed higher levels of morning LH concentrations than non-obese girls, as well as a significant correlation between morning LH and testosterone levels. This association suggests that LH is a permissive factor for androgen excess, since LH is the proximal stimulus for androgen production by ovarian theca cells. And, in susceptible girls, free androgens would interfere with normal negative feedback mechanism at the GnRH pulse generator, increasing both GnRH and LH pulses and the LH/FSH ratio, thereby enhancing theca androgen production [28–31]. This means, it seems that not only obesity or hyperinsulinemia but also other factors, such as pubertal levels of gonadotropins, would be included in the pathogenesis of hyper-androgenemia. In fact, several authors have considered LH, followed by fasting insulin, as the best predictor of hyper-androgenemia in obese peri-pubertal girls [8, 21].

Interestingly, the different authors who have studied hyper-androgenemia throughout pubertal transition in girls with obesity have obviated morning ACTH levels [8, 19, 32]. However, in this study, we found that early-pubertal girls with obesity showed higher levels of ACTH than non-obese girls. The reticular zone of the adrenal gland functionally resembles the theca cells of the ovary for androgen production, but in response to their trophic hormone (ACTH). Therefore, this eventuality would mean that the adrenal gland appears to be a source of excessive androgen production in early-pubertal girls with obesity (ACTH-dependent adrenal source) and, consequently, a contributor to adiposity-related hyper-androgenemia in these patients. This hypothesis would support the concept that a mixed adrenal and ovarian over-secretion of androgens in early-puberty girls with obesity could be a facilitating factor for the development of hyper-androgenemia [11, 33].

Hyper-androgenemia often has no clinical manifestations during early puberty, but despite its subclinical manifestations, it may represent a precursor of adult PCOS. In fact, different authors consider that resistance to insulin and elevated levels of androgen would be the main causes of polycystic ovarian syndrome [13, 34]. Thus, the association between peri-pubertal obesity and hyper-androgenemia may suggest that girls with obesity are at high risk for future PCOS. In fact, several authors have suggested that all adolescent girls with obesity should be asked about possible symptoms of PCOS [12, 14, 29], and some authors have even suggested the possibility of defining a condition of "PCOS secondary to
obesity” [35]. Nevertheless, prospective longitudinal research studies will be helpful to understand the natural history of girls considered to be at risk for PCOS. Obviously, our findings evidence that early-puberty girls with obesity display an abnormal hormonal profile with POCS-like features.

An important limitation of our study is the cross-sectional design and, therefore, our findings reflect an association, but do not prove causality. However, the data obtained agree with the following working hypothesis concerning obesity-related hyper-androgenemia: in some obese peri-pubertal girls, excessive IGF-1 and insulin act in synergy with ACTH and LH to stimulate the production of androgens from adrenocortical cells and ovarian theca cells respectively [7]. In addition, SHBG was not measured in this study because our laboratory routinely determines the free fraction of testosterone by highly sensitive chemiluminescence immunoassays; and therefore in this study, we were unable to verify if SHBG levels were decreased among early-pubertal girls with obesity. On the other hand, data about girls who were “at risk of overweight” (BMI-for-age between 85 and 95th percentile) are not included in this study since they are generally at intermediate risk for obesity-related abnormalities.

In conclusion, the results obtained support our hypothesis that, in early-pubertal girls with obesity, an abnormal hormonal profile with POCS-like features can already be observed. In fact, they display a hormonal profile characterized by endocrinological dysfunction (increased secretion of LH with normal FSH) together with metabolic dysfunction (insulin resistance and hyperinsulinemia) and dysfunction of ovarian/adrenal steroidogenesis (overproduction of ovarian and adrenal androgens). Additional studies are required to determine if weight loss and/or pharmacological treatment could improve both insulin resistance and decrease androgen levels in these patients.

Appendix

Hormonal profile in obese peri-pubertal girls

See Tables 3 and 4.

Table 3 Clinical characteristics (age and BMI-SDS) and hormonal measurements (leptin, TSH, FT4, IGF-1, IGFBP3, PL, insulin and HOMA-IR) in prepubertal and early subgroups according to the BMI status (median and interquartile range)

|                         | Control group (n = 132) | Obesity group (n = 165) | p values* |
|-------------------------|-------------------------|-------------------------|-----------|
| Prepubertal subgroup    |                         |                         |           |
| Age (years)             | 8.1 (8.0–8.5)           | 8.2 (7.8–8.5)           | 0.864     |
| BMI-SDS                 | −0.02 (−0.12–0.39)      | 3.3 (2.5–3.9)           | 0.001     |
| Leptin (μg/L)           | 6.1 (3.7–10.8)          | 25.2 (19.2–34.5)        | 0.006     |
| TSH (mU/L)              | 1.98 (1.4–2.1)          | 2.1 (1.5–2.8)           | 0.328     |
| FT4 (ng/dL)             | 1.0 (0.9–1.0)           | 1.0 (0.9–1.1)           | 0.207     |
| IGF-1 (μg/L)            | 177.1 (148.2–207.2)     | 179.0 (149.6–214.1)     | 0.872     |
| IGFBP3 (μg/L)           | 4860.1 (4485.3–5387.1)  | 5090.2 (4453.3–5617.5)  | 0.628     |
| PL (μg/L)               | 10.8 (8.0–14.2)         | 10.3 (8.4–13.9)         | 0.556     |
| Insulin (mU/L)          | 6.9 (5.1–9.8)           | 13.2 (8.9–17.9)         | 0.001     |
| HOMA-IR                 | 1.5 (1.1–2.3)           | 2.9 (2.1–4.0)           | 0.001     |
|                         | Control group (n = 111) | Obesity group (n = 118) |           |
| Early puberty subgroup  |                         |                         |           |
| Age (years)             | 9.9 (9.3–10.5)          | 10.2 (9.4–10.9)         | 0.831     |
| BMI-SDS                 | 0.10 (−0.7–0.5)         | 3.2 (2.3–3.7)           | 0.001     |
| Leptin (μg/L)           | 8.5 (6.3–12.2)          | 43.9 (35.4–55.6)        | 0.001     |
| TSH (mU/L)              | 2.1 (1.5–2.7)           | 2.2 (1.6–2.9)           | 0.643     |
| FT4 (ng/dL)             | 1.0 (0.9–1.1)           | 0.9 (0.8–1.0)           | 0.682     |
| IGF-1 (μg/L)            | 256.1 (210.5–312.4)     | 345.6 (267.2–424.4)     | 0.378     |
| IGFBP3 (μg/L)           | 5705.4 (5160.3–6172.5)  | 6370.2 (5370.6–7457.4)  | 0.288     |
| PL (μg/L)               | 9.3 (7.3–13.2)          | 11.1 (8.1–15.4)         | 0.210     |
| Insulin (mU/L)          | 11.8 (6.3–14.6)         | 22.3 (15.6–31.4)        | 0.001     |
| HOMA-IR                 | 2.3 (1.5–3.2)           | 4.5 (3.7–6.9)           | 0.001     |

*Mann–Whitney U test
Table 4 Hormonal determinations (FSH, LH, estradiol, ACTH, cortisol, 17-OH-P, DHE-S, androstendiona, T and FT) in prepubertal and early subgroups according to the BMI status (median and interquartile range)

|                      | Control group (n = 132) | Obesity group (n = 165) | p values* |
|----------------------|-------------------------|-------------------------|-----------|
| **Prepubertal subgroup** |                         |                         |           |
| FSH (UI/L)           | 1.4 (0.8–1.9)           | 1.5 (0.6–1.9)           | 0.632     |
| LH (UI/L)            | 0.0 (0.02–0.07)         | 0.04 (0.02–0.05)        | 0.451     |
| Estradiol (pg/mL)    | 9.1 (6.3–9.9)           | 9.2 (9.0–9.7)           | 0.830     |
| ACTH (ng/L)          | 18.1 (13.5–24.8)        | 21.9 (15.1–28.2)        | 0.234     |
| Cortisol (μg/dL)     | 7.9 (5.3–10.6)          | 7.4 (5.1–10.9)          | 0.411     |
| 17-OH-P (μg/L)       | 0.7 (0.5–0.9)           | 0.7 (0.5–1.1)           | 0.908     |
| DHE-S (μg/dL)        | 62.1 (45.9–78.7)        | 66.6 (43.3–81.45)       | 0.532     |
| Androstenedione (μg/L)| 0.3 (0.3–0.4)           | 0.3 (0.3–0.4)           | 0.934     |
| Testosterone (ng/mL) | 0.1 (0.06–0.1)          | 0.1 (0.08–0.1)          | 0.744     |
| FT (ng/L)            | 0.3 (0.1–0.5)           | 0.2 (0.1–0.5)           | 0.331     |
|                      |                         |                         |           |
| **Early puberty subgroup** |                     |                         |           |
| FSH (UI/L)           | 3.6 (2.5–4.8)           | 4.2 (2.3–5.3)           | 0.163     |
| LH (UI/L)            | 0.4 (0.2–1.1)           | 2.3 (0.8–3.9)           | 0.001     |
| Estradiol (pg/mL)    | 21.6 (14.6–41.1)        | 28.0 (18.4–33.5)        | 0.810     |
| ACTH (ng/L)          | 15.1 (13.9–24.5)        | 27.7 (20.7–38.1)        | 0.013     |
| Cortisol (μg/dL)     | 8.2 (5.6–10.9)          | 10.0 (7.1–12.9)         | 0.240     |
| 17-OH-P (μg/L)       | 0.7 (0.5–0.9)           | 0.9 (0.6–1.2)           | 0.322     |
| DHE-S (μg/dL)        | 65.1 (49.3–87.1)        | 138.2 (97.2–166.9)      | 0.001     |
| Androstenedione (μg/L)| 0.5 (0.3–0.7)           | 1.3 (0.8–1.7)           | 0.001     |
| Testosterone (ng/mL) | 0.13 (0.09–0.15)        | 0.21 (0.18–0.285)       | 0.001     |
| FT (ng/L)            | 0.5 (0.3–0.9)           | 1.2 (0.7–1.7)           | 0.001     |

*Mann–Whitney U test

Author contributions  TDT participated in study design and data analysis, and wrote the first draft of the manuscript. FGV participated in data collection and analysis. All authors participated in manuscript preparation and approved its final version.

Funding  Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors received no financial support for the research, authorship, and/or publication of this article (none declared).

Data availability  The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest  The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article (none declared).

Ethical approval  This study was approved by the Ethics Committee for Human Investigation of the Navarra Hospital Complex, Pamplona, Spain (code: 14/27) in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and later amendments.

Informed consent  Parents and/or legal guardians were appropriately informed and gave consent for the participation of the participants in this study in all cases.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Lissau I, Overpeck MD, Ruan WJ, Due P, Holstein Hediger ML (2004) Body mass index and overweight in adolescents in 13 European countries, Israel, and the United States. Arch Pediatr Adolesc Med 158:27–33

2. Lobstein T, Jackson-Leach R, Moodie ML, Hall KD, Gortmaker SL, Swinburn BA et al (2015) Child and adolescent obesity: part of a bigger picture. Lancet 385:2510–2520

3. Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA et al (2011) Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 365:1876–1885

4. Kelly AS, Barlow SE, Hayman L, Steinberger J et al (2013) Severe obesity in children and adolescents: Identification, associated health risks, and treatment approaches: a scientific statement from the American heart association. Circulation 128:1689–1712

5. Skinner AC, Perrin EM, Moss LA, Skelton JA (2015) Cardiometabolic risks and severity of obesity in children and young adults. N Engl J Med 373:1307–1317

6. Branca F, Nikogosian H, Lobstein T (2007) The challenge of obesity in the WHO European region and the strategies for response. World Health Organization, Copenhagen. Available in http://www.euro.who.int/document/e89858.pdf

7. Burt Solorzano CM, McCartney CR (2010) Obesity and the pubertal transition in girls and boys. Reproduction 140:399–410

8. Knudsen KL, Blank SK, Burt Solorzano C, Patrie JT, Chang RJ, Caprio S, Marshall JC, McCartney CR (2010) Hyperandrogenemia in obese peripubertal girls: correlates and potential etiological determinants. Obesity (Silver Spring) 18:2118–2124

9. Burt Solorzano CM, Knudsen KL, Anderson AD, Hutchens EG, Collins JS, Patrie JT, Marshall JC, McCartney CR (2018) Insulin resistance, hyperinsulinemia, and LH: relative roles in peripubertal obesity-associated hyperandrogenemia. J Clin Endocrinol Metab 103(7):2571–2582

10. Bordini B, Littlejohn E, Rosenfield RL (2009) Blunted sleep-related luteinizing hormone rise in healthy premenarcheal pubertal girls with elevated body mass index. J Clin Endocrinol Metab 94:1168–1175

11. Burt Solorzano CM, Helm KD, Patrie JT, Shaya RF, Cook-Andersen HL, Chang RJ, McCartney CR, Marshall JC (2017) Increased adrenal androgens in overweight peripubertal girls. J Endocr Soc 1:538–552

12. Anderson AD, Burt Solorzano CM, McCartney CR (2014) Childhood obesity and its impact on the development of adolescent PCOS. Semin Reprod Med 32:202–213

13. Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, Xie Q (2021) Resistance to the insulin and elevated level of androgen: a major cause of polycystic ovary syndrome. Front Endocrinol (Lausanne) 12:741764

14. Ibañez L, Oberfield SE, Witchel SF, Aucus RJ, Chang RJ, Codner E et al (2017) An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 88:371–395

15. Velfer YA, Phillip M, Shalitin S (2019) Increased prevalence of severe obesity and related comorbidities among patients referred to a pediatric obesity clinic during the last decade. Horm Res Paediatr 92:169–178

16. Ferrández A, Baguer L, Labarta JI, Labena C, Mayayo E, Puga B, Rueda C, Ruiz-Echarri M (2005) Estudio longitudinal de niños españoles normales desde el nacimiento hasta la edad adulta, 1st edn. Fundación Andrea Prader, Zaragoza

17. Reinherz T, de Souza G, Roth CL, Andler W (2005) Androgens before and after weight loss in obese children. J Clin Endocrinol Metab 90:5588–5595

18. Du X, Rosenfield RL, Qin K (2009) KLF15 is a transcriptional regulator of the human 17-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. J Clin Endocrinol Metab 94:2594–2601

19. Kang MJ, Yang S, Hwang IT (2016) The impact of obesity on hyperandrogenemia in Korean girls. Ann Pediatr Endocrinol Metab 21:219–225

20. Durá-Travé T, Fidel Gallinas-Victoriano F, Urrutavizcaya-Martínez M, Ahmed-Mohamed L, Chueca-Guiñulai ML, Berrade-Zubiri S (2020) Effects of the application of a prolonged combined intervention on body composition in adolescents with obesity. Nutr J 19:49

21. Rosenfield RJ, Ehrmann DA (2016) The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 37:467–520

22. L’Allemand D, Schmidt S, Rousson V, Brabant G, Gasser T, Gruters A (2002) Associations between body mass, leptin, IGFI and circulating adrenal androgens in children with obesity and premature adrenarche. Eur J Endocrinol 146:537–543

23. Zheng SH, Du DF, Li XL (2017) Leptin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Reprod Sci 24:656–670

24. Teixeira RJ, Ginzberg D, Rodrigues Freitas J, Fucks G, Silva CM, Bordallo MA (2004) Serum leptin levels in premature pubarche and prepubertal girls with and without obesity. J Pediatr Endocrinol Metab 17:1393–1398

25. Rosenfield RL, Mortensen S, Wroblewski K, Littlejohn E, Ehrmann DA (2011) Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 26:3138–3146

26. Frystyk J, Skjaerbaeck C, Vestbo E, Fisker S, Orskov H (1999) Circulating levels of free insulin-like growth factors in obese subjects: the impact in type 2 diabetes. Diabetes Metab Res Rev 15:314–322

27. Freemark M (2005) Metabolic consequences of obesity and their management. In: Brooks Ch, Claytoin P, Brown R (eds) Clinical pediatric endocrinology. Blackwell Publishing Ltd, Oxford, pp 419–435

28. Blanck SK, McCartney CR, Chhabra S, Helm KD, Eagleson CA, Chang RJ, Marshall JC (2009) Modulation of GnRH pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls—implications for regulation of puberal maturation. J Clin Endocrinol Metab 94:2360–2366

29. McCartney CR (2010) Maturation of sleep-wake gonadotrophin-releasing hormone secretion across puberty in girls: potential mechanisms and relevance to the pathogenesis of polycystic ovary syndrome. J Neuroendocrinol 22:701–709

30. Burt Solorzano CM, McCartney CR, Blank SK, Knudsen KL, Marshall JC (2010) Hyperandrogenemia in adolescent girls: origins of abnormal gonadotropin-releasing hormone secretion. BJOG 117:143–149

31. Burt Solorzano CM, Bella JP, Abshire MY, Collins JS, McCartney CR, Marshall JC (2012) Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 77:332–337

32. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, Yoo R, Chang RJ, Foster CM, Caprio S, Marshall JC (2007) Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab 92:430–4366

33. Burt Solorzano CM, McCartney CR (2021) Polycystic ovary syndrome: ontogeny in adolescence. Endocrinol Metab Clin North Am 50:25–42
34. Pasquali R, Oriolo C (2019) Obesity and androgens in women. In: Pasquali R, Pignatelli D (eds) Hyperandrogenism in women. Beyond polycystic ovary syndrome, vol 53. Karger, Basel, pp 120–134

35. Pasquali R, Gambineri A (2018) New perspectives on the definition and management of polycystic ovary syndrome. J Endocrinol Invest 41:1123–1135

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.